Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach, grich1
Search This Board: 
Last Post: 2/18/2018 4:27:30 AM - Followers: 69 - Board type: Free - Posts Today: 2

NTRPD Security Details
Share Structure

Market Value1 $54,718,000 a/o Jan 24, 2019
Authorized Shares 150,000,000 a/o October 23, 2017
Outstanding Shares 7,895,859 a/o October 23, 2017
Warrants: 5.1M
Mgt Options: 680K
Fully diluted: (shares out+warrants+options): 13.7M
Float 1,627,372 a/o Jan 12, 2017


Dr Alkon patents

Nobel Presentation links 

2018 Bio Ceo conference 

Phase 2a and compassionate use patient results

Neurotrope's Bryostatin Improves Cognition in Patients with Advanced Alzheimer's Disease Based on Further Analysis of Phase 2 Clinical Trial Data

PR NewswireJanuary 5, 2018
                                                                                                                  - Improvements in cognition found in advanced Alzheimer's disease patients receiving 20μg bryostatin in absence of background memantine therapy -                                                                                                                                                        - Sustained improvements in cognition observed 30 days after last dose suggest improvements in underlying disease -

- Confirmatory clinical trial planned in advanced Alzheimer's disease, non-memantine patients -

NEW YORK, Jan. 5, 2018 /PRNewswire/ -- Neurotrope (NTRP) today announced that a post-hoc analysis of data from its Phase 2 trial in patients with advanced Alzheimer's disease (AD) found evidence of improvement in cognition in patients receiving the 20μg bryostatin regimen who did not receive memantine, an approved AD treatment, as background therapy. The findings suggest this investigational drug could potentially help treat the progression of AD, rather than only its symptoms. The findings will be presented by Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope in a keynote presentation at the Sachs' Neuroscience Innovation Forum on January 7 in San Francisco.

The follow-on analysis also found that patients in the 20μg treatment arm showed a sustained improvement in cognition over baseline compared to the placebo group at week 15 (30 days after last dose at week 11). These data were observed in the study population as a whole.

"These findings are intriguing and warrant further study to confirm whether the observed treatment benefit can be replicated and enhanced," said Martin R. Farlow, MD, Vice Chairman for Research in the Department of Neurology, Indiana University School of Medicine, Indiana Alzheimer Disease Center, who previously presented the top-line data from Neurotrope's study at the 2017 Alzheimer's Association International Conference. 

Memantine, an NMDA receptor antagonist, is marketed under the brand names Namenda®, Namenda® XR, and Namzaric® (a combination of memantine and donepezil) for the treatment of dementia in patients with moderate-to-severe AD. It has been shown to delay cognitive decline and help reduce disease symptoms. The interaction between NMDA function and protein kinase C (PKC) has been well studied, and the scientific rationale elucidating the interactions are explored in many peer reviewed publications. 

"The discovery that an NMDA inhibitor like memantine may diminish the effect of bryostatin, a PKC epsilon activator is very interesting as it is consistent with the proposed mode of action of bryostatin, and provides an internal control within the trial. This represents one of the most promising new developments in AD research and is welcome news following so many heartbreaking disappointments in the field," said George Perry, PhD, Semmes Foundation University Chair in Neurobiology, and Dean of the College of Sciences at The University of Texas at San Antonio, an internationally recognized leader in AD research who recently joined Neurotrope's Board as a Director. "These findings suggest that, for the first time, we may be able to reverse cognitive decline and actually improve cognition in people with moderate-to-severe Alzheimer's disease. It will be important to further investigate these results with confirmatory studies."

In this exploratory Phase 2 study in 150 patients with advanced AD, two doses of bryostatin (20μg and 40μg) were compared with controls to assess safety and preliminary efficacy after 12 weeks of treatment. The pre-specified primary endpoint, the Severe Impairment Battery (SIB) used to evaluate cognition in severe dementia, compared each dose of bryostatin with controls at week 13 in two sets of patients: 1) the modified intent-to-treat (mITT) population (consisting of all patients who received the study drug and had at least one efficacy/safety evaluation), and 2) the Completers population (consisting of those patients within the mITT population who completed the 13-week assessment). As previously reported, the 20μg dose was found to be safe and well tolerated, and showed evidence of sustained improvement in cognition compared to controls, while the 40μg dose did not show an improvement in cognition.

The follow-on analysis of the data evaluated SIB scores of patients at 15 weeks, 30 days after all dosing had been completed. For the 20μg group, patients in the mITT population (n=34) showed an overall improvement compared to controls (n=33) of 3.59 (p=0.0503) and in the Completers population (n=34) showed an overall improvement compared to controls (n=33) of 4.09 (p=0.0293). In summary, patients on the 20μg dose showed a persistent SIB improvement 30 days after all dosing had been completed. These p-values and those below are one-tailed.


The post-hoc analysis comparing SIB scores in non-memantine versus memantine patients found the following:

  • At week 15, non-memantine patients in the mITT Group treated with 20μg (n=14) showed an SIB improvement of 5.88, while the placebo patients (n=11) showed a decline in their SIB scores of -0.05 for an overall treatment Δ of 5.93 from baseline (p=0.0576). 

    At week 15, non-memantine patients in the Completers Group treated with 20μg (n=14) showed an SIB improvement of 6.24, while the placebo patients (n=11) showed a decline in their SIB scores of -0.12 for an overall treatment Δ of 6.36 from baseline (p=0.0488). 

    Patients taking memantine as background therapy in the 20μg (n=20) and control (n=22) groups showed no improvement in SIB scores.

Neurotrope is planning a confirmatory study in advanced AD patients not taking memantine as background therapy to evaluate whether the improvements in SIB scores in those patients can be replicated. The company is in discussions with a leading academic institution to design and conduct the trial, which is expected to begin in the first half of 2018.

"Neurotrope's next clinical trial will focus on the 20μg dose, which showed evidence of sustained cognitive improvement in advanced Alzheimer's disease patients," said Dr. Alkon. "It will be designed to confirm, with increased power, the increases in SIB scores observed among memantine-free patients in the recently completed Phase 2 trial. The company has the financial resources required to complete the planned study." 


About Neurotrope

Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.

In addition to the Company's Phase 2 trial of bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of bryostatin as a potential treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome—three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs in AD.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP News: Amended Statement of Ownership (sc 13g/a) 02/14/2018 05:59:12 PM
NTRP News: Neurotrope to Present at BIO CEO & Investor Conference 02/07/2018 08:30:00 AM
NTRP News: Neurotrope to Present at NobleCon 14th Annual Institutional Investor Conference 01/25/2018 08:30:00 AM
NTRP News: Current Report Filing (8-k) 01/08/2018 09:01:48 AM
NTRP News: Neurotrope's Bryostatin Improves Cognition in Patients with Advanced Alzheimer's Disease Based on Further Analysis of Phase 2... 01/05/2018 09:28:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#5741  Sticky Note Here are all the relevant full articles I've Cyosol 02/11/18 06:21:15 PM
#5681  Sticky Note Here's the corporate presentation: Cyosol 02/05/18 01:55:24 PM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#5783   I think this abstract describes it well: Cyosol 02/18/18 04:27:30 AM
#5782   The thing that makes Bryostatin 1 so damn Cyosol 02/18/18 04:11:28 AM
#5781   I'm far from a medical professional but having Whoopddew 02/17/18 09:45:11 PM
#5780   Yes, I agree. Intriguing the positive effect InTheTrenches 02/17/18 06:51:38 PM
#5779   The test which they used for that research runncoach 02/17/18 06:44:13 PM
#5778   That is interesting pre-clinical data. InTheTrenches 02/17/18 06:40:15 PM
#5777   Interesting abstract posted this week on research into runncoach 02/17/18 01:09:21 PM
#5776   After the last data release I can't imagine Whoopddew 02/17/18 11:10:37 AM
#5775   Closed out the year right on 14% institutional runncoach 02/17/18 08:27:01 AM
#5774   New CEO new trial getting ready to happen Whoopddew 02/16/18 06:21:21 PM
#5773   That's the beauty of it Trenches and we runncoach 02/16/18 06:43:22 AM
#5772   This was the most recent research provided on runncoach 02/16/18 06:34:23 AM
#5771   Not only has Dr. Alkon confirmed that Bryostatin Cyosol 02/15/18 11:53:33 PM
#5770   If the PKC-e theory is proven out in InTheTrenches 02/15/18 11:05:43 PM
#5769   Good point - "That could benefit us at XenaLives 02/15/18 10:46:55 PM
#5768   It's probably true that the industry has given runncoach 02/15/18 08:37:47 PM
#5767   Severe stage is never addressed because the industry Cyosol 02/15/18 08:28:40 PM
#5766   That could benefit us at some point but runncoach 02/15/18 08:20:15 PM
#5765   "FDA Opens New Path for Alzheimer's Treatments" Cyosol 02/15/18 08:07:46 PM
#5764   That is true. Admitting you are wrong is Cyosol 02/15/18 07:15:22 PM
#5763   It would be an admission that they wasted Selett 02/15/18 04:35:05 PM
#5762   New CEO starts his work as of today FYI Cyosol 02/15/18 12:56:30 PM
#5761   Ownership now at 13.38 with SUSQUEHANNA INTERNATIONAL GROUP, runncoach 02/15/18 08:14:19 AM
#5760   Institutional ownership now up to 13.11% with CANNELL runncoach 02/14/18 02:52:45 PM
#5759   Just seen the article about Merck when this Whoopddew 02/14/18 11:18:14 AM
#5758   As far as an oral formulation goes, yesterday's runncoach 02/14/18 08:10:05 AM
#5757   Here's another interesting fact: Cyosol 02/14/18 04:49:17 AM
#5756   It seems we may all be in very Whoopddew 02/13/18 10:46:37 PM
#5755   Unfortunate for the patients. No doubt we runncoach 02/13/18 10:23:47 PM
#5754   Unfortunate for them maybe. For us this is Cyosol 02/13/18 10:08:41 PM
#5753   New stroke/tbi patent issued today fyi. Alkon has runncoach 02/13/18 09:48:40 PM
#5752   Unfortunately another failure of BP. runncoach 02/13/18 09:42:42 PM
#5751   Minute 13:10 : InTheTrenches 02/13/18 06:12:20 PM
#5750   I don't believe there are any unfortunately. runncoach 02/13/18 05:55:18 PM
#5749   Just wondering if any patients from last trial Whoopddew 02/13/18 05:22:15 PM
#5748   Not much new. Stated that confirmatory trial runncoach 02/13/18 04:32:29 PM
#5747   Thx Grinch runncoach 02/13/18 04:08:28 PM
#5746   Yesterday's presentation is on NTRP website. grich1 02/13/18 03:23:47 PM
#5745   Game never ends watching the bid I think Whoopddew 02/12/18 12:36:13 PM
#5744   I agree. Eom runncoach 02/12/18 10:40:38 AM
#5743   Trading Very hard to buy - the bid moves Biostudent 02/12/18 10:36:09 AM
#5742   Premarket. Looks like someone wanted that 100 shares pretty runncoach 02/12/18 08:22:08 AM
#5741   Here are all the relevant full articles I've Cyosol 02/11/18 06:21:15 PM
#5740   Cyosol if you really want to have fun runncoach 02/11/18 05:28:43 PM
#5739   This is the scientific reality. Very small float LaurieM 02/11/18 04:04:07 PM
#5738   Here's an article on how Bryostatin 1 "Restores Cyosol 02/11/18 03:02:31 PM
#5737   For those interested in further reading, here's an Cyosol 02/11/18 02:30:31 PM
#5736   They have orphan drug status for fragile X Whoopddew 02/10/18 08:31:11 PM
#5735   First things first, lets just try to get runncoach 02/09/18 07:11:01 PM
#5734   Sorry if that wasn't stated correctly I was Whoopddew 02/09/18 07:03:13 PM